Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia

N. S. Nurmohamed, G. M. Dallinga–Thie, E. S.G. Stroes*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review


Introduction: The prevalence of hypertriglyceridemia (HTG) is increasing. Elevated triglyceride (TG) levels are associated with an increased cardiovascular disease (CVD) risk. Moreover, severe HTG results in an elevated risk of pancreatitis, especially in severe HTG with an up to 350-fold increased risk. Both problems emphasize the clinical need for effective TG lowering. Areas covered: The purpose of this review is to discuss the currently available therapies and to elaborate the most promising novel therapeutics for TG lowering. Expert opinion: Conventional lipid lowering strategies do not efficiently lower plasma TG levels, leaving a residual CVD and pancreatitis risk. Both apolipoprotein C-III (apoC-III) and angiopoietin-like 3 (ANGPTL3) are important regulators in TG-rich lipoprotein (TRL) metabolism. Several novel agents targeting these linchpins have ended phase II/III trials. Volanesorsen targeting apoC-III has shown reductions in plasma TG levels up to 90%. Multiple ANGPLT3 inhibitors (evinacumab, IONIS-ANGPTL3-LRx, ARO-ANG3) effectuate TG reductions up to 70% with concomitant potent reduction in all other apoB containing lipoprotein fractions. We expect these therapeutics to become players in the treatment for (especially) severe HTG in the near future.

Original languageEnglish
Pages (from-to)355-361
Number of pages7
JournalExpert Review of Cardiovascular Therapy
Issue number6
Publication statusPublished - 2 Jun 2020

Cite this